Emerald Advisers LLC Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Emerald Advisers LLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 7.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 898,190 shares of the specialty pharmaceutical company's stock after buying an additional 62,140 shares during the quarter. Emerald Advisers LLC owned 1.81% of KalVista Pharmaceuticals worth $10,365,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the fourth quarter worth about $44,000. GAMMA Investing LLC increased its stake in shares of KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after purchasing an additional 3,767 shares during the period. Tower Research Capital LLC TRC increased its stake in KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares during the period. Legal & General Group Plc increased its stake in KalVista Pharmaceuticals by 22.5% during the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company's stock valued at $69,000 after acquiring an additional 1,494 shares during the period. Finally, Martin Worley Group bought a new position in KalVista Pharmaceuticals during the fourth quarter valued at about $86,000.

Insider Activity

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the firm's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.69, for a total value of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares of the company's stock, valued at $5,798,945.55. This trade represents a 8.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Paul K. Audhya sold 2,776 shares of KalVista Pharmaceuticals stock in a transaction on Monday, May 19th. The stock was sold at an average price of $11.84, for a total transaction of $32,867.84. Following the sale, the insider directly owned 106,611 shares of the company's stock, valued at $1,262,274.24. This represents a 2.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,878 shares of company stock valued at $723,617. Company insiders own 10.50% of the company's stock.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock traded down $0.99 during trading on Friday, hitting $14.52. The company's stock had a trading volume of 2,085,829 shares, compared to its average volume of 572,060. The stock has a market cap of $721.93 million, a price-to-earnings ratio of -3.93 and a beta of -0.04. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.32. The stock has a 50-day moving average price of $12.57 and a two-hundred day moving average price of $11.25.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($2.86). During the same period in the prior year, the company earned ($1.07) EPS. On average, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on KALV. Leerink Partners upped their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Jones Trading reiterated a "buy" rating and issued a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. JMP Securities raised their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. Finally, HC Wainwright raised their price objective on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $26.29.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).